Evidence map›Paper›PMID 34130961›Full record

Observational studyBMJ open2021

Risk factors for severity on admission and the disease progression during hospitalisation in a large cohort of patients with COVID-19 in Japan.

Mari Terada, Hiroshi Ohtsu, Sho Saito, Kayoko Hayakawa, Shinya Tsuzuki, Yusuke Asai, Nobuaki Matsunaga, Satoshi Kutsuna, Wataru Sugiura, Norio Ohmagari

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in BMJ open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 3 pooled it
8.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 3 syntheses or guidelines pooled it, 132 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. JSH2024 smoke-free declaration "Stop All Tobacco Products".Hypertension research : official journal of the Japanese Society of Hypertension · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Clinical features in patients with COVID-19 treated with biologics for severe asthma.The journal of allergy and clinical immunology. Global · 2024
    Article
  15. Article
  16. Article
  17. The relation between proteinuria and the severity of COVID-19.Clinical and experimental nephrology · 2024
    Article
  18. Article
  19. Article
  20. Article

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Mari TeradaDepartment of Infectious Diseases, Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Hiroshi OhtsuCenter for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.ORCID 0000-0003-3261-8828
Sho SaitoDepartment of Infectious Diseases, Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan ssaito@hosp.ncgm.go.jp.ORCID 0000-0002-9981-7584
Kayoko HayakawaDepartment of Infectious Diseases, Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Shinya TsuzukiAMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japan.ORCID 0000-0002-8504-1244
Yusuke AsaiAMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japan.
Nobuaki MatsunagaAMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japan.
Satoshi KutsunaDepartment of Infectious Diseases, Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Wataru SugiuraCenter for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.
Norio OhmagariDepartment of Infectious Diseases, Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
National Center for Global Health and Medicine · JPUniversity of Antwerp · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo investigate the risk factors contributing to severity on admission. Additionally, risk factors of worst severity and fatality were studied. Moreover, factors were compared based on three points: early severity, worst severity and fatality.

designAn observational cohort study using data entered in a Japan nationwide COVID-19 inpatient registry, COVIREGI-JP.

settingAs of 28 September 2020, 10480 cases from 802 facilities have been registered. Participating facilities cover a wide range of hospitals where patients with COVID-19 are admitted in Japan.

participantsParticipants who had a positive test result on any applicable SARS-CoV-2 diagnostic tests were admitted to participating healthcare facilities. A total of 3829 cases were identified from 16 January to 31 May 2020, of which 3376 cases were included in this study. PRIMARY AND SECONDARY OUTCOME MEASURES: Primary outcome was severe or nonsevere on admission, determined by the requirement of mechanical ventilation or oxygen therapy, SpO2 or respiratory rate. Secondary outcome was the worst severity during hospitalisation, judged by the requirement of oxygen and/orinvasive mechanical ventilation/extracorporeal membrane oxygenation.

resultsRisk factors for severity on admission were older age, men, cardiovascular disease, chronic respiratory disease, diabetes, obesity and hypertension. Cerebrovascular disease, liver disease, renal disease or dialysis, solid tumour and hyperlipidaemia did not influence severity on admission; however, it influenced worst severity. Fatality rates for obesity, hypertension and hyperlipidaemia were relatively lower.

conclusionsThis study segregated the comorbidities influencing severity and death. It is possible that risk factors for severity on admission, worst severity and fatality are not consistent and may be propelled by different factors. Specifically, while hypertension, hyperlipidaemia and obesity had major effect on worst severity, their impact was mild on fatality in the Japanese population. Some studies contradict our results; therefore, detailed analyses, considering in-hospital treatments, are needed for validation. TRIAL REGISTRATION NUMBER: UMIN000039873. https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000045453.

Indexed as

COVID-19AgedCohort StudiesDisease ProgressionHospitalizationHumansJapanMaleRisk FactorsSARS-CoV-2Treatment OutcomeCOVID-19epidemiologyvirology

Identifiers

PMID34130961
PMCPMC8210659
OpenAlexW3167210620

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.